Full textPDF
Full text
DIAGNOSIS
The haematological condition is acute myeloid leukaemia and the syndrome in this patient is tuberous sclerosis. Tuberous sclerosis is an inherited neurocutaneous syndrome characterised by multiple benign hamartomas involving brain, eyes, heart, lung, liver, kidney, and skin.1 It has an autosomal dominant pattern of inheritance with an approximate incidence of 1 in 5000 to 10,000 live births.2 Tuberous sclerosis can be diagnosed clinically using the criteria from the International Tuberous Sclerosis Complex Consensus Conference.3 Patients with tuberous sclerosis are at an increased risk of developing malignant tumours involving kidneys, brain, and soft tissues.4 The risk of malignancy in tuberous sclerosis is approximately 18-fold higher than in the normal population. Downregulation of tuberous sclerosis complex 2 expression has been demonstrated in acute myeloid leukaemia.5
REFERENCES
- Schwartz RA, Fernández G, Kotulska K, Jóźwiak S. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol. 2007;57:189.
- Hallett L, Foster T, Liu Z, et al. Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic review. Curr Med Res Opin. 2011;27:1571.
- Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49:243.
- Al-Saleem T, Wessner LL, Scheithauer BW, et al. Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer. 1998;83:2208.
- Xu Z, Wang M, Wang L, et al. Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia. Leuk Res. 2009;33:891-7.